Federal Register / Vol. 79, No. 221 / Monday, November 17, 2014 / Notices 68455 

Dated: November 10, 2014. 

Leslie Kux, 

Assistant Commissioner for Policy. 

[FR Doc. 2014–27039 Filed 11–14–14; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Advisory Commission on Childhood 

Vaccines; Notice of Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Public Law 92–463), notice is hereby 

given of the following meeting: 

Name: Advisory Commission on 

Childhood Vaccines (ACCV) 

Date And Time: December 4, 2014, 

10:00 a.m. to 4:00 p.m. EDT 

Place: Audio Conference Call and 

Adobe Connect Pro 

The ACCV will meet on Thursday, 

December 4, 2014, from 10:00 a.m. to 

4:00 p.m. (EDT). The public can join the 

meeting by: 

1. (Audio Portion) Calling the 

conference Phone Number 877–917– 

4913 and providing the following 

information: 

Leader’s Name: Dr. A. Melissa Houston 

Password: ACCV 

2. (Visual Portion) Connecting to the 

ACCV Adobe Connect Pro Meeting 

using the following URL: https://

hrsa.connectsolutions.com/accv/ (copy 

and paste the link into your browser if 

it does not work directly, and enter as 

a guest). Participants should call and 

connect 15 minutes prior to the meeting 

in order for logistics to be set up. If you 

have never attended an Adobe Connect 

meeting, please test your connection 

using the following URL: https://

hrsa.connectsolutions.com/common/

help/en/support/meeting_test.htm and 

get a quick overview by following URL: 

http://www.adobe.com/go/connectpro_

overview. Call (301) 443–6634 or send 

an email to aherzog@hrsa.gov if you are 

having trouble connecting to the 

meeting site. 

Agenda: The agenda items for the 

December 2014 meeting will include, 

but are not limited to: updates from the 

Division of Injury Compensation 

Programs (DICP), Department of Justice 

(DOJ), National Vaccine Program Office 

(NVPO), Immunization Safety Office 

(Centers for Disease Control and 

Prevention), National Institute of 

Allergy and Infectious Diseases 

(National Institutes of Health), and the 

Center for Biologics, Evaluation and 

Research (Food and Drug 

Administration). A draft agenda and 

additional meeting materials will be 

posted on the ACCV Web site (http://

www.hrsa.gov/vaccinecompensation/

accv.htm) prior to the meeting. Agenda 

items are subject to change as priorities 

dictate. 

Public Comment: Persons interested 

in providing an oral presentation should 

submit a written request, along with a 

copy of their presentation to: Annie 

Herzog, DICP, Healthcare Systems 

Bureau (HSB), Health Resources and 

Services Administration (HRSA), Room 

11C–26, 5600 Fishers Lane, Rockville, 

MD 20857 or email: aherzog@hrsa.gov. 

Requests should contain the name, 

address, telephone number, email 

address, and any business or 

professional affiliation of the person 

desiring to make an oral presentation. 

Groups having similar interests are 

requested to combine their comments 

and present them through a single 

representative. The allocation of time 

may be adjusted to accommodate the 

level of expressed interest. DVIC will 

notify each presenter by email, mail, or 

telephone of their assigned presentation 

time. Persons who do not file an 

advance request for a presentation, but 

desire to make an oral statement, may 

announce it at the time of the public 

comment period. Public participation 

and ability to comment will be limited 

to space and time as it permits. 

FOR FURTHER INFORMATION CONTACT: 

Anyone requiring information regarding 

the ACCV should contact Annie Herzog, 

DICP, HSB, HRSA, Room 11C–26, 5600 

Fishers Lane, Rockville, Maryland 

20857, telephone (301) 443–6593, or 

email: aherzog@hrsa.gov. 

Dated: November 7, 2014. 

Jackie Painter, 

Acting Director, Division of Policy and 

Information Coordination. 

[FR Doc. 2014–27188 Filed 11–14–14; 8:45 am] 

BILLING CODE 6705–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 209 and 37 CFR Part 404 to 

achieve expeditious commercialization 

of results of federally-funded research 

and development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

U.S. patent applications listed below 

may be obtained by writing to the 

indicated licensing contact at the Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

SUPPLEMENTARY INFORMATION: 

Technology descriptions follow. 

Heterocyclic Compounds for the 

Treatment of Hepatitis C Virus 

Description of Technology: The vast 

majority of people infected with 

Hepatitis C Virus (HCV) will have 

chronic infection. Over decades, this 

can lead to liver disease and liver 

cancer. In fact, HCV infection is the 

leading cause of liver transplants in the 

U.S. Several new drugs have recently 

come into the market that have changed 

the HCV treatment paradigm. However, 

the effectiveness of these new drugs can 

vary depending on the HCV genotype. 

Furthermore, all oral, interferon free 

therapeutic regimens for HCV infection 

will need combinations of drugs that 

target different aspects of the HCV life 

cycle. Thus, there is still the need for 

additional new therapeutics against 

HCV. 

The subject technologies are 

aryloxazole based small molecules that 

are potent inhibitors of HCV infection 

and replication. The compounds exhibit 

synergy with currently available 

therapeutics for HCV and represent a 

new class of anti-HCV compounds. The 

compounds affect the entry step of HCV 

infection, a step not targeted by 

currently available therapeutics against 

HCV. 

Potential Commercial Applications: 

Prevention and treatment of HCV 

infection. 

Competitive Advantages: 

• Potent inhibitors of HCV infection 

and replication. 

• Show synergistic effect with 

currently available HCV therapeutics. 

• Represent new class of HCV 

inhibitors that target the entry step of 

HCV infection. 

Development Stage: 

• Early-stage. 

• In vitro data available. 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
68456 Federal Register / Vol. 79, No. 221 / Monday, November 17, 2014 / Notices 

Inventors: Jake Tsanyang Liang 

(NIDDK), Zongyi Hu (NIDDK), Juan Jose 

Marugan (NCATS), Noel Terrance 

Southhall (NCATS), Xin Hu (NCATS), 

Jingbo Xiao (NCATS), Shanshan He 

(NIDDK), Marc Ferrer-Alegre (NCATS), 

Wei Zhang (NCATS) 

Intellectual Property: HHS Reference 

No. E–161–2014/0—U.S. Provisional 

Patent Application No. 62/011,462 filed 

12 June2014 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018; changke@

mail.nih.gov 

Autodock Vina Software Process for 

Efficient Large-Scale Cognate Ligand 

Screening 

Description of Technology: The 

invention pertains to software 

processes, additions, and docking 

approaches to Autodock Vina that 

speeds the rate and efficiency of 

analyzing ligand interactions with a 

receptor by cognate ligands and rewards 

conformations in the scoring algorithm 

for residue interactions that are based 

on the biological data. The score is 

multiplied by a weighting factor to 

control the degree of ligand-residue 

interactions that are considered. This 

multiplier is then added to the docking 

score for confirmation. This new scoring 

mechanism is used to score each 

compound in each generation of the 

evolutionary genetic algorithm. This 

docking approach can be used to score 

and rank compounds in large-scale 

virtual screening applications. The 

software includes logic for converting 

SDF formatted to an Autodock Vina 

compatible format (containing approx. 

25,000 compounds each) and submits 

the job to the portable batch system on 

the computing cluster to convert into 

PDBC files (a concatenated filed type). 

Modified Vina software stores the 

analyzed binding pocket in RAM that 

does not have to be recomputed upon 

every docking process. This increases 

the efficiency of the docking algorithm 

by several orders of magnitude. The 

software on the head node intelligently 

monitors memory usage, CPU usage and 

docking speed. Based on this 

information, the head node elastically 

controls the load on each node. 

Potential Commercial Applications: 

• Drug screening. 

• Ligand identification. 

Competitive Advantages: 

• Speed. 

• Batch processing. 

• Efficient CPU processing. 

Development Stage: In vitro data 

available. 

Inventors: Marvin Gershengorn, 

Umesh Padia, Janak Padia, Elizabeth 

Geras-Raaka (all of NIDDK). 

Intellectual Property: HHS Reference 

No. E–289–2014/0—Software Tool. 

Patent protection is not being pursued 

for this technology. 

Licensing Contact: Michael 

Shmilovich, Esq.; 301–435–5019; 

shmilovm@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institutes of Diabetes and 

Digestive and Kidney Diseases is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate or commercialize 

Cognate Ligand Identification. For 

collaboration opportunities, please 

contact Anna Amar at 301–451–2305 or 

aamar@mail.nih.gov. 

Dated: November 10, 2014. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2014–27083 Filed 11–14–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health: 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

NIMH Career Transition Award for TenureTrack and Tenured Intramural Investigators 

(K22). 

Date: December 2, 2014. 

Time: 12:30 p.m. to 1:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Ingrid Y. Li, Ph.D., Health 

Science Administrator Division of 

Extramural Activities, National Institute of 

Mental Health, NIH Neuroscience Center, 

6001 Executive Blvd., Room 6154–C, 

Bethesda, MD 20892, 301–443–1421, 

ili1@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.242, Mental Health Research 

Grants, National Institutes of Health, HHS) 

Dated: November 7, 2014. 

Carolyn A. Baum, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–27060 Filed 11–14–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Environmental Health Sciences Special 

Emphasis Panel; Alternative Toxicological 

Methods Support Contract for the National 

Toxicology Program (NTP). 

Date: December 11, 2014. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Environmental 

Health Sciences, Keystone Building, 

Conference Room 2166, 530 Davis Drive, 

Research Triangle Park, NC 27709, 

(Telephone Conference Call). 

Contact Person: RoseAnne M. McGee, 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research and 

Training, Nat. Institute of Environmental 

Health Sciences, P.O. Box 12233, MD EC–30, 

Research Triangle Park, NC 27709 (919) 541– 

0752, mcgee1@niehs.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 


asabaliauskas on DSK5VPTVN1PROD with NOTICES